Evaluation and management of gastrointestinal manifestations in scleroderma

Current Opinion in Rheumatology

Volumn 26, Issue 6, 2014, Pages 621-629

  Kirby, Donald F ^a   Chatterjee, Soumya ^b  

^a Digestive Disease Institute   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Chronic intestinal pseudo obstruction; Dysphagia; Faecal incontinence; Gastroesophageal reflux disease; Gastroparesis; Small intestinal bacterial overgrowth; Systemic sclerosis

Indexed keywords

ANTIBODY; PROBIOTIC AGENT; RNA POLYMERASE III ANTIBODY; UNCLASSIFIED DRUG;

BARRETT ESOPHAGUS; CHRONIC INTESTINAL PSEUDO OBSTRUCTION; COLON DIVERTICULOSIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS DISEASE; ESOPHAGUS DYSMOTILITY; ESOPHAGUS STENOSIS; FECES INCONTINENCE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY DISORDER; HUMAN; INTESTINE DIVERTICULOSIS; INTESTINE INFECTION; INTESTINE OBSTRUCTION; MASTICATION DISEASE; MEGACOLON; MOUTH DISEASE; MOUTH MALFORMATION; NARROW ORAL APERTURE; PANCREAS EXOCRINE INSUFFICIENCY; PATHOGENESIS; PATIENT CARE; PNEUMATOSIS INTESTINALIS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; QUESTIONNAIRE; RECTUM PROLAPSE; REVIEW; SCLERODERMA; SJOEGREN SYNDROME; SMALL INTESTINAL BACTERIAL OVERGROWTH; STOMACH ANTRUM VASCULAR ECTASIA; STOMACH PARESIS; STOMACH ULCER; SYSTEMIC SCLEROSIS; TOOTH DISEASE; COMPLICATION; DISEASE MANAGEMENT; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; PATHOLOGY;

DISEASE MANAGEMENT; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; SCLERODERMA, SYSTEMIC;

EID: 84927713622     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000117     Document Type: Review

References (66)

1. Turner R, Lipshutz W, Miller W, et al. Esophageal dysfunction in collagen disease. Am J Med Sci 1973; 265:191-199.
2. Akesson A, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol 1989; 28:281-286.
3. Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010; 39:269-277.
4. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69:1809-1815.
5. Recasens MA, Puig C, Ortiz-Santamaria V. Nutrition in systemic sclerosis. Reumatol Clin 2012; 8:135-140.
6. Omair MA, Lee P. Effect of gastrointestinal manifestations on quality of life in 87 consecutive patients with systemic sclerosis. J Rheumatol 2012; 39:992-996.
7. Harrison E, Herrick AL, McLaughlin JT, Lal S. Malnutrition in systemic sclerosis. Rheumatology (Oxford) 2012; 51:1747-1756.
8. Caporali R, Caccialanza R, Bonino C, et al. Disease-related malnutrition in outpatients with systemic sclerosis. Clin Nutr 2012; 31:666-671.
9. Rajapakse CN, Bancewicz J, Jones CJ, Jayson MI. Pharyngo-oesophageal dysphagia in systemic sclerosis. Ann Rheum Dis 1981; 40:612-614.
10. Montesi A, Pesaresi A, Cavalli ML, et al. Oropharyngeal and esophageal function in scleroderma. Dysphagia 1991; 6:219-223.
11. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013; 108:308-328.
12. Thonhofer R, Siegel C, Trummer M, Graninger W. Early endoscopy in systemic sclerosis without gastrointestinal symptoms. Rheumatol Int 2012; 32:165-168.
13. Gyger G, Baron M. Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management. Curr Rheumatol Rep 2012; 14:22-29.
14. Zhang XJ, Bonner A, Hudson M, et al. Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis. J Rheumatol 2013; 40:850-858.
15. Christmann RB, Wells AU, Capelozzi VL, Silver RM. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum 2010; 40:241-249.
16. Hendel L, Aggestrup S, Stentoft P. Long-term ranitidine in progressive systemic sclerosis (scleroderma) with gastroesophageal reflux. Scand J Gastroenterol 1986; 21:799-805.
17. Hendel L, Hage E, Hendel J, Stentoft P. Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis. Aliment Pharmacol Ther 1992; 6:565-577.
18. Reimer C. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol 2013; 27:443-454.
19. Wilhelm SM, Rjater RG, Kale-Pradhan PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol 2013; 6:443-451.
20. Targownik LE, Leslie WD, Davison KS, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 2012; 107:1361-1369.
21. Florentin M, Elisaf MS. Proton pump inhibitor-induced hypomagnesemia: a new challenge. World J Nephrol 2012; 1:151-154.
22. El-Charabaty E, Saifan C, Abdallah M, et al. Effects of proton pump inhibitors and electrolyte disturbances on arrhythmias. Int J Gen Med 2013; 6:515-518.
23. Tang DM, Pathikonda M, Harrison M, et al. Symptoms and esophageal motility based on phenotypic findings of scleroderma. Dis Esophagus 2013; 26:197-203.
24. Lahcene M, Oumnia N, Matougui N, et al. Esophageal involvement in scleroderma: clinical, endoscopic, and manometric features. ISRN Rheumatol 2011; 2011:325826.
25. Kikendall JW. Pill esophagitis. J Clin Gastroenterol 1999; 28:298-305.
26. Abid S, Mumtaz K, Jafri W, et al. Pill-induced esophageal injury: endoscopic features and clinical outcomes. Endoscopy 2005; 37:740-744.
27. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 2011; 140:e18-e52.
28. Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther 2013; 15 (Suppl 3):S5.
29. Ingraham KM, O'Brien MS, Shenin M, et al. Gastric antral vascular ectasia in systemic sclerosis: demographics and disease predictors. J Rheumatol 2010; 37:603-607.
30. Swanson E, Mahgoub A, MacDonald R, Shaukat A. Medical and endoscopic therapies for angiodysplasia and gastric antral vascular ectasia: a systematic review. Clin Gastroenterol Hepatol 2014; 12:571-582.
31. Keohane J, Berro W, Harewood GC, et al. Band ligation of gastric antral vascular ectasia is a safe and effective endoscopic treatment. Dig Endosc 2013; 25:392-396.
32. Ghrenassia E, Avouac J, Khanna D, et al. Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. J Rheumatol 2014; 41:99-105.
33. Camilleri M, Parkman HP, Shafi MA, et al. Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013; 108:18-37.
34. Fynne L, Worsoe J, Gregersen T, et al. Gastrointestinal transit in patients with systemic sclerosis. Scand J Gastroenterol 2011; 46:1187-1193.
35. Savarino E, Mei F, Parodi A, et al. Gastrointestinal motility disorder assessment in systemic sclerosis. Rheumatology (Oxford) 2013; 52:1095-1100.
36. Lata PF, Pigarelli DL. Chronic metoclopramide therapy for diabetic gastroparesis. Ann Pharmacother 2003; 37:122-126.
37. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010; 31:11-19.
38. Parkman HP, Mishra A, Jacobs M, et al. Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters. J Clin Gastroenterol 2012; 46:494-503.
39. Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 1990; 322:1028-1031.
40. Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 1993; 88:203-207.
41. Soykan I, Sarosiek I, McCallum RW. The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. Am J Gastroenterol 1997; 92:976-980.
42. Parkman HP, Jacobs MR, Mishra A, et al. Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. Dig Dis Sci 2011; 56:115-124.
43. Paine P, McLaughlin J, Lal S. Review article: the assessment and management of chronic severe gastrointestinal dysmotility in adults. Aliment Pharmacol Ther 2013; 38:1209-1229.
44. Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol 2010; 16:2978-2990.
45. Abu-Shakra M, Guillemin F, Lee P. Gastrointestinal manifestations of systemic sclerosis. Semin Arthritis Rheum 1994; 24:29-39.
46. Frech TM, Khanna D, Maranian P, et al. Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/distention. Clin Exp Rheumatol 2011; 29:S22-S25.
47. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991; 325:1461-1467.
48. Sallam HS, McNearney TA, Chen JD. Acupuncture-based modalities: novel alternative approaches in the treatment of gastrointestinal dysmotility in patients with systemic sclerosis. Explore (NY) 2014; 10:44-52.
49. Shah AA, Wigley FM. My approach to the treatment of scleroderma. Mayo Clin Proc 2013; 88:377-393.
50. Butt S, Emmanuel A. Systemic sclerosis and the gut. Expert Rev Gastroenterol Hepatol 2013; 7:331-339.
51. Thoua NM, Schizas A, Forbes A, et al. Internal anal sphincter atrophy in patients with systemic sclerosis. Rheumatology (Oxford) 2011; 50:1596-1602.
52. Thoua NM, Abdel-Halim M, Forbes A, et al. Fecal incontinence in systemic sclerosis is secondary to neuropathy. Am J Gastroenterol 2012; 107:597-603.
53. Sallam HS, McNearney TA, Chen JZ. Anorectal motility and sensation abnormalities and its correlation with anorectal symptoms in patients with systemic sclerosis: a preliminary study. ISRN Gastroenterol 2011; 2011:402583.
54. De SM, Crotti C, Selmi C. Liver abnormalities in connective tissue diseases. Best Pract Res Clin Gastroenterol 2013; 27:543-551.
55. Norman GL, Bialek A, Encabo S, et al. Is prevalence of PBC underestimated in patients with systemic sclerosis? Dig Liver Dis 2009; 41:762-764.
56. Assassi S, Fritzler MJ, Arnett FC, et al. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol 2009; 36:2250-2256.
57. Jacobsen S, Halberg P, Ullman S, et al. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol 1998; 37:39-45.
58. Imura-Kumada S, Hasegawa M, Matsushita T, et al. High prevalence of primary biliary cirrhosis and disease-associated autoantibodies in Japanese patients with systemic sclerosis. Mod Rheumatol 2012; 22:892-898.
59. Cavazzana I, Ceribelli A, Taraborelli M, et al. Primary biliary cirrhosis-related autoantibodies in a large cohort of Italian patients with systemic sclerosis. J Rheumatol 2011; 38:2180-2185.
60. Rigamonti C, Shand LM, Feudjo M, et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006; 55:388-394.
61. Shawis TN, Chaloner C, Herrick AL, Jayson MI. Pancreatic function in systemic sclerosis. Br J Rheumatol 1996; 35:298-299.
62. Cobden I, Axon AT, Rowell NR. Pancreatic exocrine function in systemic sclerosis. Br J Dermatol 1981; 105:189-193.
63. Baron M, Hudson M, Steele R. Malnutrition is common in systemic sclerosis: results from the Canadian scleroderma research group database. J Rheumatol 2009; 36:2737-2743.
64. Berry AJ. Pancreatic enzyme replacement therapy during pancreatic insufficiency. Nutr Clin Pract 2014; 29:312-321.
65. Khanna D, Nagaraja V, Gladue H, et al. Measuring response in the gastrointestinal tract in systemic sclerosis. Curr Opin Rheumatol 2013; 25:700-706.
66. Baron M, Hudson M, Steele R, Lo E. Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis. J Rheumatol 2011; 38:1925-1930.